Acute lymphoblastic leukemia (ALL) is a hematological disease that is characterized by the proliferation of immature lymphoid cells in the bone marrow and peripheral blood. ALL is typically a disease of childhood, with over 70% of cases affecting children. Current treatment regimens have led to a cure rate of approximately 80% for children with ALL. However, the long-term prognosis for adult patients with ALL remains poor, with cure rates of only 30–40%.
The launches of generic tyrosine kinase inhibitors and emergence of CAR-T therapies will reshape the ALL market.
TKIs are widely incorporated into treatment strategies for both adult and AYA patients with Ph+ ALL.
Incident cases of ALL are expected to increase, and prognosis remains poor – especially among older adults.
Generic erosion will signal an end to Gleevec’s Ph+ ALL dominance as targeted therapies build momentum.